Recruiting

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning

Beijing Tiantan Hosptial, Capital Medical University, Beijing